Nano Mobile Healthcare, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In USD, except per-share amounts

	FY2015 12 months to Jun 30, 2016	FY2014 12 months to Jun 30, 2015	FY2012 12 months to Jun 30, 2013
Cash Flows from Operating Activities
Net (loss) income
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Deposit impairment
Unrealized loss on investment
Debt discount
Loss (Gain) on derivative liability
Loss on equity swap
Warrants issued for services
Shares issued for services
Depreciation
Loss attributable to non-controlling interest
Bad debt expense

Changes in assets and liabilities
(Increase) decrease in interest receivable
Increase (decrease) in accounts payable and accrued expenses
Prepaid expense
Accounts payable and accrued expenses

Net cash used in operating activities
Cash Flows from Investing Activities
Cash paid for deposit
Cash paid for acquisition of 51% interest in Moxisign
Purchase of fixed assets
Net cash used in investing activities

Cash Flows from Financing Activities
Proceeds from sales of common stock
Proceeds from related party debt
Payments on related party debt
Proceeds from convertible notes payable
Proceeds on loans payable
Payments on loans payable
Net cash from financing activities

Foreign exchange adjustment
Net change in cash
Cash, beginning of period
Cash, end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for tax
Exercise of stock warrants for stock subscription receivable

Non-Cash investing and financing transactions
Common stock issued to settle related party debt
Write-off of stock subscription receivable
Common stock issued for for coversion of parent company stock
Common stock issued to settle convertible debt
Recognition of derivative debt discount
Conversion of derivative liability
Reclassifaction of tainted warrants to derivitive liability

Comments